

1

2 Rapid and simultaneous identification of three mutations by the Novaplex™

3 SARS-CoV-2 Variants I Assay kit¹

4

5 Wakaki Kami^a, Takeshi Kinjo^a, Wakako Arakaki^a, Hiroya Oki^b, Daisuke Motooka^b,

6 Shota Nakamura^b, and Jiro Fujita^a

7

8

9 ^aDepartment of Infectious, Respiratory and Digestive Medicine, Graduate School

10 of Medicine, University of the Ryukyus. Address: 207 Uehara Nishihara,

11 Okinawa 903-0215, Japan

¹ Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VOC, variant of concern; VOI, variant of interest; WHO, World Health Organization

12 ^bDepartment of Infection Metagenomics, Genome Information Research Center,

13 Research Institute for Microbial Diseases. Address: 3-1 Yamadaoka, Suita,

14 Osaka 565-0871, Japan

15

16

17 Correspondence to:

18 Takeshi Kinjo, MD, PhD

19 207 Uehara, Nishihara, Okinawa 903-0215, Japan

20 Phone number: +81-98-895-1144

21 Fax number: +81-98-895-1414

22 E-mail address: t_kinjo@med.u-ryukyu.ac.jp

23

24

25 **Abstract**

26 Background: The emergence of SARS-CoV-2 variants has caused an
27 unexpected rebound globally. The World Health Organization has listed three
28 variants (B.1.1.7, B.1.351, and P.1) as variants of concern. To understand the
29 epidemiology and thereby plan appropriate safety measures, differential
30 identification of the variants is indeed critical.

31 Objectives: Although whole-genome sequencing is the gold standard for variant
32 identification, it is time-consuming and relatively expensive. Therefore, a rapid,
33 easy, and cost-effective platform targeting multiple regions of the genome is
34 required. Here, we assessed the usefulness of the Novaplex™ SARS-CoV-2
35 Variants I Assay kit in identifying mutations in the variants.

36 Study design: We retrospectively examined 30 stored nasal swabs from
37 COVID-19-positive patients tested between November 2020 and March 2021.

38 RNA extracted from these swabs was subjected to the commercial kit and
39 real-time reverse transcription-PCR was performed. To determine the genome
40 sequences of SARS-CoV-2 in the collected samples and deduce the consensus
41 sequences among the identified variants, genome sequencing libraries were
42 prepared and mapped to the reference genome.

43 Results: Four of the tested samples were determined as variants. Of them, two
44 harbored both H69/V70 deletion and N501Y substitution, whereas two harbored
45 E484K substitution alone.

46 Conclusions: The variant with E484K substitution alone (“R.1”) has been now
47 categorized as a variant of interest in Japan. Additionally, the kit-based assay
48 was found to be feasible, convenient, and user-friendly in identifying the
49 abovementioned mutations with a turnaround time of only 2 hours.

50

51 Keywords: SARS-CoV-2, COVID-19, variant, mutations, whole-genome

52 sequencing

53

54

55 **Introduction**

56 Although the global advent of vaccines against severe acute respiratory

57 syndrome coronavirus 2 (SARS-CoV-2) has relieved us from the ongoing

58 pandemic, the emergence of SARS-CoV-2 variants has raised new concerns.

59 The World Health Organization (WHO) defines a SARS-CoV-2 variant of interest

60 (VOI) as a phenotypically changed isolate that causes community transmission

61 or clusters, and a variant of concern (VOC) as a VOI with increased

62 transmissibility and virulence, or decreased effectiveness of public health and

63 social measures or diagnostics, vaccines, and treatment [1]. As of April 13, 2021,

64 WHO has listed three VOCs: B.1.1.7, B.1.351, and P.1, named the UK variant,
65 South Africa variant, and Brazil/Japan variant, respectively, after the places
66 where they were first identified [2]. Among the various mutations emerging in
67 SARS-CoV-2, those in the spike (S) protein, specifically the H69/V70 deletion
68 and E484K N501Y substitution mutations, are important because the S protein is
69 involved in infectivity to host cells via angiotensin-converting enzyme 2 and the
70 main target of neutralizing antibodies induced by vaccines [3]. All three VOCs
71 listed above harbor the N501Y mutation; B.1.1.7 harbors an additional H69/V70
72 deletion; and the other two, the E484K substitution mutation. Each mutation
73 alone and in combination determines the phenotypic features of the variants,
74 such as transmissibility and severity of the coronavirus disease 2019
75 (COVID-19), and vaccine effectiveness [3,4]. Therefore, prompt differentiation of
76 the SARS-CoV-2 variants is critical to monitor the epidemic situation in the

77 community and to perform adequate infection control and patient care.

78 Currently, whole genome or complete/partial S-gene sequencing is the
79 gold standard for differentiating SARS-CoV-2 variants [5]. However, genome
80 sequencing requires professional and technical expertise, knowledge of data
81 analysis, and high-end facilities. Additionally, it is time-consuming, laborious, and
82 relatively expensive. Given these circumstances, a rapid, easy, and
83 cost-effective platform targeting multiple regions of the SARS-CoV-2 genome is
84 required [6]. NovaplexTM SARS-CoV-2 Variants I Assay is a newly developed
85 multiplex real-time reverse transcription-PCR kit capable of identifying multiple
86 mutations, including the abovementioned ones in a single reaction within 2 hours.
87 Here, we report the utility of this commercial kit and discuss its implications in the
88 differential identification of SARS-CoV-2 variants.

89

90 **Materials and Methods**

91 We retrospectively examined the stored nasal swabs from
92 COVID-19-positive patients tested at the Ryukyu University Hospital between
93 November 2020 and March 2021. COVID-19 diagnosis was confirmed by
94 real-time PCR with primer sets developed by the National Institute for Infectious
95 Diseases of Japan [7]. RNA was extracted from the nasal swabs stored in a
96 deep freezer using MagLEAD 12gC (Precision System Science, Chiba, Japan).
97 The extracted RNA was then subjected to the Novaplex™ SARS-CoV-2 Variants
98 I Assay kit (Seegene, Seoul, South Korea) according to the manufacturer's
99 instructions using the CFX96 Touch Real-Time PCR Detection System (Bio-Rad,
100 Hercules, CA, USA). The test result, either plus or minus, was automatically
101 displayed on the system's monitor with the kit-accompanied software Seegene
102 Viewer V1.0 (Seegene). To determine the genome sequences of SARS-CoV-2 in

103 the collected samples, next-generation sequencing libraries were prepared
104 using the multiplex PCR method. Briefly, after reverse transcription using
105 SuperScript IV Reverse Transcriptase (Thermo Fisher Scientific, Waltham, MA,
106 USA) and random primers pd(N)₆ (Takara Bio, Shiga, Japan), whole genome
107 amplification was conducted using ATRIC Network's modified (V3) primer set [8].
108 Libraries were prepared using the Nextera XT Library Prep Kit (Illumina, San
109 Diego, CA, USA) and 2 x 151 paired-end sequencing was performed on a MiSeq
110 platform (Illumina, San Diego, CA, USA) with the respective MiSeq v3 Reagent
111 kit. After mapping to the reference genome of SARS-CoV-2 (GenBank accession
112 number: NC_045512.2), consensus sequences were obtained using CLC
113 Genomics Workbench ver. 21.0.2 (QIAGEN, Hilden, Germany). This study was
114 approved by the Institutional Review Board of the University of the Ryukyus
115 (approval number: 1621).

116

117 **Results**

118 A total of 30 COVID-19-positive samples were tested. Among them, four

119 samples collected between February and March were determined to be variants;

120 two (cases 1 and 2) were positive for both H69/V70 deletion and N501Y

121 substitution mutations (UK variant), while the other two (cases 3 and 4) were

122 positive for E484K substitution mutation alone (Table 1). These results were

123 confirmed by whole-genome sequencing (Figure 1). In terms of usability of the

124 NovaplexTM SARS-CoV-2 Variants I Assay kit, the procedure was simple and

125 easy to perform, and the turnaround time was only 120 minutes (Figure 2).

126

127 Figure 1. Genome sequences of the variants detected in this study.

128 Genome sequence data for the four cases are shown. Reference sequences

129 (Wuhan and Okinawa) and typical mutation patterns are shown in the upper and
130 lower stands, respectively.

131

132 Figure 2. Procedure for real-time reverse transcription-PCR using the
133 commercial Seegene kit and system.

134 PCR mixture was prepared using the extracted RNA and Novaplex™
135 SARS-CoV-2 Variants I Assay kit reagents; real-time reverse transcription-PCR
136 was performed using the CFX96 Touch Real-Time PCR Detection System. The
137 test results were automatically displayed on the monitor via the software's
138 interface (Seegene Viewer).

139

140 **Discussion**

141 Many countries are now facing an unexpected rebound of the COVID-19

142 pandemic, mainly attributable to the emergence of several SARS-CoV-2 variants.

143 Therefore, prompt identification of the variants is critical for controlling disease

144 spread. Although genome sequencing is considered the gold standard for

145 identifying SARS-CoV-2 variants, it has several limitations in terms of swiftness

146 and convenience. In Japan, as of April 23, 2021, randomly selected

147 COVID-19-positive samples were tested for the N501Y mutation at local public

148 health institutes and affiliated hospitals, and the positive samples along with a

149 few negative ones were sent to a central public health institute (National Institute

150 of Infectious Diseases, Tokyo, Japan) for whole-genome sequencing [9].

151 Although dependent upon several factors, such as the local situation of the

152 COVID-19 epidemic and geographical conditions, it usually takes a week to

153 receive the final report of genome sequencing. This limitation can be overcome

154 by the Novaplex™ SARS-CoV-2 Variants I Assay kit that can substantially

155 shorten the turnaround time.

156 Since many variants are emerging, there is a possibility that
157 monoplex-based testing can miss detecting some of the characteristic mutations
158 in the variants. We detected two samples with the E484K mutation and without
159 the N501Y mutation in this study. This variant has been named R.1 and
160 categorized as a VOI in Japan as of April 7, 2021; however, this variant could
161 bypass the screening stage in our country. Therefore, we need a
162 multiplex-based test that can examine several mutations simultaneously.

163 In conclusion, the Novaplex™ SARS-CoV-2 Variants I Assay is a simple,
164 rapid, and easy to perform method, and can identify three important mutations
165 simultaneously. An additional advantage of this commercial kit is that it can be
166 used with conventional real-time thermal cyclers. We believe that the
167 widespread application of this kit can help in the convenient identification of the

168 viral variants.

169

170 **Declaration of competing interest**

171 The authors have no conflicts to declare.

172

173 **Acknowledgements**

174 We would like to thank Editage (www.editage.com) for English language editing.

175 We also thank Dr. Kentaro Tanaka for his technical support in performing

176 genome analysis.

177

178 **Funding**

179 None.

180

181 **References**

182 [1] World Health Organization, COVID-19 weekly epidemiological update.

183 Special edition: Proposed working definitions of SARS-CoV-2 variants of interest

184 and variants of concern, 2021.

185 <https://www.who.int/docs/default-source/coronaviruse/situation-reports/20210222>

186 [5_weekly_epi_update_voc-special-edition.pdf?sfvrsn=1eacfa47_7&download=tr](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20210222-5-weekly-epi-update-voc-special-edition.pdf?sfvrsn=1eacfa47_7&download=true)

187 [ue](#).

188 [2] World Health Organization, Weekly epidemiological update on

189 COVID-19, 2021.

190 <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covi>

191 [d-19---13-april-2021](#).

192 [3] C.E. Gómez, B. Perdiguero, M. Esteban, Emerging SARS-CoV-2

193 variants and impact in global vaccination programs against

194 SARS-CoV-2/COVID-19, Vaccines 9 (2021) 243. doi:

195 <https://doi.org/10.3390/vaccines9030243>.

196 [4] G. Nelson, O. Buzko, P. Spilman, K. Niazi, S. Rabizadeh, P.

197 Soon-Shiong, Molecular dynamics simulation reveals E484K mutation enhances

198 spike RBD-ACE2 affinity and the combination of E484K K417n and N501Y

199 mutations (501Y.V2 variant) induces conformational change greater than N501Y

200 mutant alone, potentially resulting in an escape mutant, bioRxiv 2021. doi:

201 <https://doi.org/10.1101/2021.01.13.426558>.

202 [5] European Centre for Disease Prevention and Control, and World Health

203 Organization Regional Office for Europe, Methods for the detection and

204 identification of SARS-CoV-2 variants, 2021.

205 <https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-and-identification-of-SARS-CoV-2-variants-WHO-ECDC.pdf>.

206 <https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-and-identification-of-SARS-CoV-2-variants-WHO-ECDC.pdf>.

207 [6] World Health Organization, Genomic sequencing of SARS-CoV-2: A
208 guide to implementation for maximum impact on public health, 2021.
209 <https://apps.who.int/iris/handle/10665/338480>.

210 [7] K. Shirato, N. Nao, H. Katano, I. Takayama, S. Saito, F. Kato, et al,
211 Development of genetic diagnostic methods for detection for novel coronavirus
212 2019 (nCoV-2019) in Japan, Jpn. J. Infect. Dis. 73(4) (2020) 304–307. doi:
213 [10.7883/yoken.JJID.2020.061](https://doi.org/10.7883/yoken.JJID.2020.061).

214 [8] K. Itokawa, T. Sekizuka, M. Hashino, R. Tanaka, M. Kuroda,
215 Disentangling primer interactions improves SARS-CoV-2 genome sequencing
216 by multiplex tiling PCR, PLOS ONE 15(9) (2020) e0239403. doi:
217 [10.1371/journal.pone.0239403](https://doi.org/10.1371/journal.pone.0239403).

218 [9] T. Takenouchi, Y.W. Iwasaki, S. Harada, H. Ishizu, Y. Uwamino, S. Uno,
219 et al, Clinical utility of SARS-CoV-2 whole genome sequencing in deciphering

220 source of infection, J. Hosp. Infect. 107 (2021) 40–44. doi:

221 <https://doi.org/10.1016/j.jhin.2020.10.014>.

	<i>RdRP</i>	Ct	H69/V70 del	Ct	E484K	Ct	N501Y	Ct
Case 1	(+)	24.23	(+)	27.43	(-)	0.00	(+)	28.08
Case 2	(+)	38.27	(+)	37.08	(-)	0.00	(+)	37.86
Case 3	(+)	31.85	(-)	0.00	(+)	33.11	(-)	0.00
Case 4	(+)	20.22	(-)	0.00	(+)	21.25	(-)	0.00

222 Table 1. Result of PCR performed using the Novaplex™ SARS-CoV-2 Variants I Assay kit.

223 The *RdRP* gene was included in this assay to confirm the presence of SARS-CoV-2. Endogenous internal controls of all

224 samples were positive. (+) and (-) represent positive and negative, respectively. Abbreviations: del, deletion; Ct, cycle

225 threshold.

Figure 1




Figure 2

Extracted RNA



Novaplex™ SARS-CoV-2 Variants I Assay kit



Thermal cycler (42 cycles)



Seegene Viewer screen display



Preparation of PCR mixture (10 minutes)

+

PCR and data analysis (110 minutes)

=

Total assay time (2 hours)